Questcor Pharmaceuticals Inc. (QCOR) announced Tuesday morning that it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis.
Questcor Pharmaceuticals has gapped open sharply higher Tuesday and is now up 12.18 at $48.89. The stock has leaped to over an 8-month high.
For comments and feedback: editorial@rttnews.com